arrow
R

Rafał Dziadziuszko

Medical University of Gdańsk
H指数:59
被引数:1.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Adjuvant alectinib versus chemotherapy in resected ALK- positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trial

辅助阿来替尼与化疗在切除后的ALK阳性非小细胞肺癌(ALINA):一项随机、开放标签、III期试验的健康相关生活质量与安全性结果

2026-08-010
OAAI
Plain language summary of the ALINA study results: alectinib compared with chemotherapy after surgery in people with ALK-positive non-small cell lung cancer

ALINA研究结果的大众语言摘要:alectinib与化疗相比,在ALK阳性非小细胞肺癌患者术后的应用

2025-12-310
PRE
MAGELLAN arms B1 and B3: Durvalumab plus chemotherapy with and without oleclumab in treatment-naïve metastatic non-small-cell lung cancer

MAGELLAN方案B1和B3臂:在治疗初治转移性非小细胞肺癌患者中,比较度伐利尤单抗联合化疗与联合化疗并联合奥雷oclumab的疗效。

2025-11-070
PRE
\zaAlectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: Final overall survival analysis of the Phase III ALEX study

阿来替尼对比克唑替尼用于初治ALK阳性晚期非小细胞肺癌:III期ALEX研究最终总生存期分析

2025-10-170
OAAI
Durvalumab after radiotherapy in patients with unresectable stage III non-small-cell lung cancer ineligible for chemotherapy: the DUART phase II nonrandomized controlled study☆

度伐鲁单抗在不可切除的III期非小细胞肺癌且不符合化疗指征的患者放疗后的应用:DUART II期非随机对照研究☆

2025-08-200
PREAI
Integrated transcriptomic and functional modeling reveals AKT and mTOR synergy in colorectal cancer

整合转录组学和功能建模揭示AKT和mTOR在结直肠癌中的协同作用

2025-07-310
OA
Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial

索托拉西布与多西他赛在经治KRAS G12C突变型晚期非小细胞肺癌中的颅内活性比较:一项全球性、III期、随机对照试验

2025-07-290
OAAI
Lung cancer research and treatment: global perspectives and strategic calls to action

肺癌研究与治疗: 全球视角与战略行动呼吁

2024-12-010
PRE
Whole exome sequencing (WES) analyses from IMpower133 and 6-year (y) overall survival (OS) from IMbrella A in patients (pts) with extensive-stage small cell lung cancer (ESSCLC) treated with atezolizumab (atezo)

全外显子组测序(WES)分析来自IMpower133和IMbrella A研究6年(y)总生存期(OS)的数据,来自接受阿替利珠单抗(atezo)治疗的广泛期小细胞肺癌(ESSCLC)患者(pts)。

2024-12-011
PRE
Plain language summary: tarlatamab for patients with previously treated small cell lung cancer
2024-11-120
OAAI
Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma

simlukafusp alfa (FAP-IL2v) 联合阿特珠单抗治疗复发和/或转移性宫颈鳞状细胞癌患者的抗肿瘤活性和安全性的2期研究

2024-11-011
PRE
BMS-986012 (anti-fucosyl-monosialoganglioside-1 [fuc-GM1]) with carboplatin plus etoposide plus nivolumab (CE/NIVO) as first-line (1L) therapy in extensive-stage small cell lung cancer (ES-SCLC): Interim analysis (IA) of a randomized phase II study

BMS-986012(抗岩藻糖基单唾液酸神经节苷脂-1[fuc-GM1])联合卡铂、依托泊苷和纳武利尤单抗(CE/NIVO)作为广泛期小细胞肺癌(ES-SCLC)的一线(1L)疗法:一项随机Ⅱ期研究的期中分析(IA)

2024-09-011
PRE
ALINA: Exploratory biomarker analyses in patients (pts) with resected ALK plus non-small cell lung cancer (NSCLC) treated with adjuvant alectinib vs chemotherapy (chemo)

ALINA:在接受了手术切除的ALK阳性非小细胞肺癌(NSCLC)患者中,接受辅助阿来替尼治疗与接受化疗的患者的探索性生物标志物分析

2024-09-014
PRE